ZETONNA (ciclesonide) by Azurity is pro-drug that is enzymatically hydrolyzed to a pharmacologically active metabolite, c21-desisobutyryl-ciclesonide (des-ciclesonide or rm1) following intranasal application. First approved in 2012.
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
ZETONNA (ciclesonide) is an intranasal metered aerosol corticosteroid approved in 2012 for allergic rhinitis. It is a pro-drug that converts to its active metabolite des-ciclesonide in the nasal cavity, which binds glucocorticoid receptors with 120-fold higher affinity than the parent compound. It reduces allergic inflammation by modulating multiple immune cell types and inflammatory mediators.
Product is in late-stage lifecycle with minimal Part D claims, indicating a mature, stable market position with likely flat to declining sales trajectory.
pro-drug that is enzymatically hydrolyzed to a pharmacologically active metabolite, C21-desisobutyryl-ciclesonide (des-ciclesonide or RM1) following intranasal application. Des-ciclesonide has anti-inflammatory activity with affinity for the glucocorticoid receptor that is 120-times higher than the…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Inhaled Ciclesonide Study in Preterm Infants
Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia
Effect of High Dose Ciclesonide on Asthma Control
Efficacy, Safety & Tolerability of Ciclesonide 200mcg Spray 4 Weeks Treatment for Intermittent & Persistent Rhinitis
Observational Study on Efficacy of Alvesco(Ciclesonide) in Asthma Children and Adolescent in Real Practice
Worked on ZETONNA at Azurity? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in ~2 years — expect lifecycle management and generic defense hiring
ZETONNA offers limited career growth opportunity given its LOE-approaching status and minimal current job openings. Roles focus on defensive commercial and market access strategies to protect remaining market share before generic entry. Career mobility from this product may be lateral rather than upward.